Zoetis Inc (NYSE:ZTS) reached a new 52-week high on Tuesday . The company traded as high as $136.87 and last traded at $135.73, with a volume of 7337 shares changing hands. The stock had previously closed at $136.51.

A number of research firms have recently issued reports on ZTS. Morgan Stanley lifted their target price on shares of Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research note on Monday, September 30th. Credit Suisse Group set a $138.00 target price on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, October 11th. ValuEngine cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Bank of America restated a “hold” rating and issued a $125.00 price objective on shares of Zoetis in a research report on Thursday, December 5th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a research report on Thursday, December 26th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $127.47.

The company has a debt-to-equity ratio of 2.47, a quick ratio of 3.02 and a current ratio of 4.39. The firm’s 50-day moving average is $128.14 and its two-hundred day moving average is $123.19. The stock has a market cap of $64.57 billion, a P/E ratio of 43.53, a PEG ratio of 2.94 and a beta of 0.81.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.06. Zoetis had a net margin of 23.76% and a return on equity of 70.78%. The firm had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.58 billion. During the same quarter in the previous year, the company posted $0.83 EPS. Zoetis’s revenue was up 7.0% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc will post 3.6 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Friday, January 17th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, January 16th. This is a positive change from Zoetis’s previous quarterly dividend of $0.16. Zoetis’s payout ratio is currently 21.09%.

In other Zoetis news, EVP Andrew Fenton sold 12,705 shares of Zoetis stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $120.30, for a total transaction of $1,528,411.50. Following the completion of the sale, the executive vice president now owns 21,530 shares of the company’s stock, valued at approximately $2,590,059. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction on Monday, December 16th. The stock was sold at an average price of $124.93, for a total transaction of $764,946.39. Following the sale, the executive vice president now directly owns 34,027 shares of the company’s stock, valued at approximately $4,250,993.11. The disclosure for this sale can be found here. Insiders have sold a total of 123,917 shares of company stock valued at $14,797,192 in the last ninety days. Company insiders own 0.29% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Echo Street Capital Management LLC boosted its stake in Zoetis by 46.1% in the 2nd quarter. Echo Street Capital Management LLC now owns 289,327 shares of the company’s stock worth $32,836,000 after purchasing an additional 91,304 shares during the period. Callahan Advisors LLC lifted its position in Zoetis by 80.0% during the 3rd quarter. Callahan Advisors LLC now owns 11,610 shares of the company’s stock worth $1,447,000 after buying an additional 5,160 shares in the last quarter. James Investment Research Inc. bought a new stake in Zoetis during the 3rd quarter worth about $790,000. Voya Financial Advisors Inc. lifted its position in Zoetis by 3.9% during the 3rd quarter. Voya Financial Advisors Inc. now owns 12,372 shares of the company’s stock worth $1,533,000 after buying an additional 468 shares in the last quarter. Finally, Iberiabank Corp lifted its position in Zoetis by 1,839.8% during the 3rd quarter. Iberiabank Corp now owns 46,264 shares of the company’s stock worth $5,764,000 after buying an additional 43,879 shares in the last quarter. 89.96% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile (NYSE:ZTS)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What is a capital gain?

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.